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ABSTRACT
Background Over the last 30 years, there has been
little improvement in the age of diagnosis of Duchenne
muscular dystrophy (DMD) (mean age of 4.5–4.11 years).
Aim To review the diagnostic process for DMD in boys
without a family history in order to identify where delays
occur and suggest areas for improvement.
Design A retrospective case note review.
Setting A tertiary centre for neuromuscular diseases in
England.
Patients All boys without family history diagnosed with
DMD in the last 10 years (n=20).
Outcome measures Mean age at four key steps in the
diagnostic pathway of DMD.
Results (1) Age at first reported symptoms of DMD was
32.5 (8–72) months (2.7 years). (2) First engagement of
a healthcare professional was at 42.9 (10–90) months.
(3) Creatine kinase (CK) levels were checked at 50.1
(14–91) months. (4) Diagnosis of DMD was confirmed at
51.7 (16–91) months (4.3 years). The total delay from
parental concern to diagnosis was 19.2 (4–50) months
(1.6 years).
Conclusions Our study shows an improvement in the
age of diagnosis of DMD although there continues to be
a delay in presentation to a health professional and a
delay in obtaining a CK test. To reduce these delays, we
propose screening for DMD as part of the Child Health
Surveillance Programme, in addition to lowering the
threshold for CK testing in primary care by promoting a
new DMD mnemonic MUSCLE. An earlier diagnosis of
DMD will allow timely access to genetic counselling,
standards of care and clinical trials.
INTRODUCTION
Duchenne muscular dystrophy (DMD) is an X
linked condition characterised by progressive
muscle weakness and wasting due to absence of the
protein dystrophin in the muscles. DMD is the
most common muscular dystrophy in children and
affects approximately one in every 4000 male new-
borns.1 Affected boys typically present with disor-
dered motor development or speech delay and
muscle weakness in early childhood. Without treat-
ment, the natural history of the condition is for
affected boys to lose ambulation before the age of
13 and death in their late teens or early 20s due to
respiratory or cardiac failure. Blood tests reveal ele-
vated creatine kinase (CK) levels, reflecting muscle
damage. In most cases, the diagnosis is confirmed
on genetic testing, showing a specific mutation in
the dystrophin gene. A muscle biopsy shows the
absence of dystrophin in the muscles; however, a
biopsy is now only recommended when initial
genetic testing is inconclusive or the patient has an
unusual phenotype. In these cases, a biopsy can be
a rapid means of establishing dystrophin status and
diagnosis which should still in every case be con-
firmed by sequencing. Since the introduction of
steroid treatment, nocturnal ventilation and cardiac
support in the last 10–15 years, as set out in the
National Institute of Health and Care Excellence
accredited Care Standards for DMD, clinical out-
comes as well as life expectancy have significantly
improved.2–4 A boy diagnosed with DMD today
and managed according to these Care Standards
has a good chance of living well into his 30s.
Over the last 10 years, numerous advocacy orga-
nisations (including in the UK the Muscular
Dystrophy Campaign and Action Duchenne) have
run high profile campaigns to raise both public and
professional awareness of this condition and
support clinicians and research in the field. In add-
ition, in recent years, new and promising thera-
peutic approaches have been developed, trying to
restore dystrophin expression in the muscle and
some of them are currently in clinical trials.5
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What is already known on this topic?
▸ Duchenne muscular dystrophy (DMD) is a life
limiting, muscle wasting condition. It typically
presents with delayed or disordered motor or
speech development and muscle weakness.
▸ Over the last 10 years, improved standards of
care have significantly increased the life
expectancy in DMD. In addition, new
therapeutic approaches are being developed.
▸ Nevertheless, DMD continues to be diagnosed
late. This negatively affects access to genetic
counselling, standards of care and potentially
recruitment into clinical trials.
What this study adds?
▸ The age of diagnosis of DMD has improved but
there continues to be a presentational and
diagnostic delay.
▸ To further lower the age of diagnosis, we
propose screening for DMD as part of the Child
Health Surveillance Programme for children in
the UK.
▸ We propose the mnemonic MUSCLE to raise
awareness of the features of DMD and the
importance of early creatine kinase testing in
primary care.
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However, despite all this, boys are still diagnosed relatively late
with DMD. According to published data, there has been little
improvement in lowering the mean age of diagnosis of DMD
over the past 15 years, still averaging between 4.5 and
4.11 years.6–10 However, due to improvements in management
of DMD in the last 15 years, a delayed diagnosis has an increas-
ingly negative impact on the clinical outcome. Newborn screen-
ing for DMD has been piloted in a number of centres around
the world. Wales had a newborn CK blood spot screening in
place for 21 years before being discontinued in 2011 following
issues around quality assurance of the blood spot test. Currently,
no country universally screens for DMD at birth.11
There are several reasons why a delayed diagnosis of DMD
impacts on quality of life and clinical outcome for boys. First,
an early diagnosis of DMD allows parents to make informed
decisions regarding future family planning. Second, it ensures
early access to standards of care, including steroid treatment,
physiotherapy and appropriate screening for cardiomyopathy.
Third, it allows participation in research based registries and
potentially allows access to clinical trials with new investiga-
tional drugs. Finally, if novel treatments for the condition are
approved, it has been widely suggested that any intervention
that potentially modifies the natural history of the condition
may be of greater benefit in less damaged muscles; in other
words, in younger children.
In this study, we reviewed the age of diagnosis of DMD in
our tertiary neuromuscular centre and compared this with pub-
lished data over the last 30 years, including our own data from
1999. The aim of the study was to identify points in the diag-
nostic pathway of DMD that particularly contribute to the delay
in the diagnosis and suggest specific areas for improvement.
METHODS
Clinical data for all boys with DMD diagnosed between 1
January 2003 and 1 January 2013 who attend the MRC Centre
for neuromuscular diseases in Newcastle for diagnosis and man-
agement were reviewed. Only new cases with no family history
of DMD were included in the study.
For each boy included in the study, medical notes were
reviewed for the data collected directly from parents at their
first diagnostic visit to the muscle clinic. The following informa-
tion was collected for each boy: age of first parental concerns
(this was considered the age of first symptoms), age of first spe-
cific engagement of a health professional related to these con-
cerns, age when CK levels were measured and age at which the
diagnosis was genetically confirmed. The interval between first
symptoms of DMD and first engagement with a health profes-
sional (presentational delay) and the interval between the first
visit to a health professional and eventual diagnosis with DMD
(diagnostic delay) were analysed. Information regarding symp-
toms at presentation, motor milestones, incidence of speech
delay and presence of behavioural problems at presentation was
also collected. General descriptive statistics were generated to
analyse the data. Ethical approval was not required for this
study.
RESULTS
We identified 33 boys who were diagnosed with DMD at the
MRC Centre in Newcastle over this 10-year period. Of these,
nine boys were excluded from the study due to the presence of
a positive family history of DMD. Four boys were diagnosed
with DMD following an incidental finding of elevated CK; they
were briefly analysed separately. This resulted in inclusion of 20
boys in this study.
The diagnosis of DMD was genetically confirmed in all cases.
Eight out of 20 boys had a muscle biopsy confirming absence or
near absence of dystrophin in the muscle. Eleven mothers were
found to be carriers (one carrier mother had (non-identical)
twin boys who both had DMD).
The three most common reported initial symptoms were (i)
waddling gait (11 boys), (ii) difficulty with steps (eight boys)
and (iii) falls (eight boys). In 18 out of 20 boys, there was a
concern about delayed motor development. Nevertheless, the
mean age of onset of walking (taking independent steps) in the
20 boys was 17 months (range 13–23 months). This is an inter-
esting finding as this is below the 18-month milestone by which
most healthcare professionals would raise concerns. In our
group, only three boys walked later than 18 months indicating
that the reliance on this motor milestone alone is not robust for
screening for DMD.
Speech and language delay has been reported in the DMD
population. In our cohort, speech delay was a presenting feature
in five boys and was documented in a total of nine boys (45%
of all cases) at the time of diagnosis. Behavioural problems are
also well described in DMD and concerns regarding the child’s
behaviour were reported by parents in four boys at time of diag-
nosis. These included immature behaviour (two boys), autistic
features (one boy) and unspecified (one boy).
Diagnostic pathway
The mean age of first reported symptoms of DMD was
32.5 months (2.7 years) with a range of 8–72 months (see
table 1). The first specific visit to a health professional due to
symptoms of DMD occurred between the ages of 10 and
90 months (mean 42.9 months). Initial concerns were raised
most often by the parents (13 boys) followed by school or
nursery (five boys), physiotherapist (one boy) and by the health
visitor (one boy). In most boys, the first health professional
involved was the general practitioner (GP) (11 boys), followed
by paediatrician (four boys), health visitor (three boys) and
physiotherapist (two boys).
CK levels were checked at a mean age of 50.1 months (range
14–91 months). The CK levels were checked by paediatricians
(16 boys), MRC Centre Newcastle (three boys) and a GP
(one boy). The mean age of genetic diagnosis of DMD in our
Table 1 Overview of the diagnostic pathway in Duchenne muscular dystrophy (DMD) for boys diagnosed in Newcastle
(n=20) First symptoms
First presentation to
a health professional CK test Diagnosis DMD
Mean age in months (years) 32.5 (2.7) 42.9 (3.6) 50.1 (4.2) 51.7 (4.3)
Range in months 8–72 10–90 14–91 10–91
Mean age (in months and years) at each step in the pathway for boys with DMD without a family history of the condition.
CK, creatine kinase.
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population is 51.7 months (4.3 years) with a range of 10–
91 months.
We subsequently looked in more detail at the delays between
each step in the diagnostic process. We looked at the presenta-
tional delay and diagnostic delay. The presentational delay is the
time from first reported symptoms to visiting a health profes-
sional for this specific concern. The diagnostic delay is the delay
between first visit to a health professional and diagnosis; this
delay is further broken down into the time between first visit to
a health professional and CK test and the time between CK test
and the diagnosis. The mean total delay in diagnosis is the time
from first reported symptoms to genetic confirmation of DMD.
Figure 1 displays the delays in the diagnostic pathway for
each of the 20 boys, arranged according to length of delay in
diagnosis. The presentational delay and diagnostic delay for
each boy are displayed in individual columns and in different
colours. The outliers in the graph are boy 1 and boy 20. In boy
1, there was no presentational delay as the boy visited a health
professional as soon as there were concerns regarding his motor
development. The large red column in this boy represents an
exceptionally long delay in requesting a CK test, resulting in a
subsequently much delayed final diagnosis (86 months). Boy 20,
in contrast, has no diagnostic delay as he was diagnosed within
1 month of visiting a health professional; therefore, there is no
red and green column (which graphically represents diagnostic
delay).
The mean total delay in the diagnosis is 19.2 (4–50) months.
The mean presentational delay between the first concerns of the
parents (32.5 months) and first specific engagement with a
health professional (42.9 months) is 10.4 (0–34) months. The
mean diagnostic delay between first visiting a health professional
and subsequent diagnosis of DMD is 8.8 (0–50) months. The
majority of this delay is due to a delay in obtaining a CK test,
7.2 (0–49) months. Once the CK result is available, the genetic
diagnosis of DMD is confirmed 1.6 (0–4) months later; a ter-
tiary specialist sees the child within that time in all cases.
In a small numbers of boys (n=4) where the diagnosis was
made incidentally due to CK testing during an unrelated illness,
the mean age at diagnosis was much lower at 35.3 (10–57)
months.
DISCUSSION
Our study shows that the mean age of diagnosis of DMD
patients seen in our tertiary Neuromuscular Centre in the last
10 years is 51.7 months (4.3 years) and the total delay in diag-
nosis of DMD is 19.2 months. This is an improvement com-
pared with previously published data. In the literature, the mean
age of diagnosis of DMD is 4.5–4.11 years of age and the mean
total delay in diagnosis 26.7–30 months.6 8 10 Our own data in
1999 showed a mean age of diagnosis of 4.8 years (16–
99 months) and mean total delay in diagnosis of 26.7 (1–61)
months.6
An analysis of the diagnostic process of DMD in the USA
showed a similar presentational delay to our results (13 vs
10.4 months) though the diagnostic delay was significantly
longer (15.6 vs 8.8 months).8 This was mostly due to a longer
delay in obtaining a CK test after first visit to a health profes-
sional (13 vs 7.2 months), attributed to the fact that most chil-
dren in the USA were initially seen by a health professional with
no access to CK testing (physiotherapist or speech and language
therapist). The total diagnostic delay is the USA is quoted as
30 months. In our study, 18 out of 20 children were initially
seen by a GP, paediatrician or a health visitor and therefore
should have access to a CK test. A delay of 7.2 months in
obtaining a CK test is therefore unacceptable given that all boys
were symptomatic and 18 out of 20 boys displayed delayed
motor development at their initial visit to a health professional.
An explanation for the delay in CK testing in our study is that
in 19 out of 20 cases the CK test was performed in secondary
care and therefore the time waiting to be seen significantly con-
tributed to the diagnostic delay. In our study, only one GP
requested a CK test (boy 20 in figure 1) resulting in a minimal
diagnostic delay. This illustrates that in order to lower the diag-
nostic delay in DMD, CK testing needs to be requested directly
from primary care.
Even though the presentational delay in our study is better
compared with other data, there is still a delay of 10.4 months
between parents first noticing the symptoms of DMD and even-
tually visiting a health professional. The reasons for the pro-
longed presentational delay are multifactorial: some parents may
not recognise early delayed development but more importantly
Figure 1 Display of individual delays
in diagnostic pathway Duchenne
muscular dystrophy (DMD). The X-axis
displays each individual boy (n=20).
The Y-axis represents the total delay
(in months) for each boy from first
reported symptoms (time 0 on Y-axis)
to diagnosis. This total delay is divided
into three parts. The blue part of the
column is the delay from first reported
symptoms to visiting a health
professional (Symp-HP), the red part is
the delay from visiting a health
professional to the creatine kinase test
(HP-CK) and the green part is the
delay between CK test and the
diagnosis of DMD (CK-Diagn).
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there could be a missed opportunity in primary care to identify
the early signs and symptoms of DMD in young boys. In our
study, only one health visitor referred a boy to secondary care
following observation of motor developmental problems. In the
vast majority of boys, initial concerns were raised by the parents
or a non-medically trained person, such as a teacher.
In the UK, boys (aged 0–4) visit their GP on average six times
a year and in addition have three routine health checks as part
of the Child Health Surveillance Programme.12 13 These health
checks are scheduled around the ages of 6 weeks, 1 year and
27–30 months. The 27–30-month health check is of particular
importance. The aim of this check is to review general develop-
ment, speech, social skills, behaviour, hearing and vision.13 The
timing of this screening check is similar to the mean age of first
parental concerns in boys subsequently diagnosed with DMD
(in our study 32.5 months). Therefore, this review could be an
ideal opportunity to identify possible DMD cases and reduce
the presentational delay.
Recommendations for lowering the age of diagnosis of DMD
To reduce the presentational delay in diagnosis of DMD, we
propose specific screening for DMD at the 27–30-month health
check. This could be done with the aid of a DMD mnemonic
MUSCLE (see figure 2). This mnemonic reminds health profes-
sionals of the main features of DMD and stresses the import-
ance of early CK testing. The MUSCLE mnemonic can also be
used by GPs when presented with a child with gross motor pro-
blems or speech delay. We strongly advocate CK testing in
primary care to reduce the diagnostic delay in DMD. Although
we recognise the difficulties of taking blood samples from
young children, the CK test is a cost-effective, readily available
and highly sensitive and specific test. The impact of an earlier
diagnosis should therefore support the recommendation of CK
testing in primary care, either by the GP or a direct referral to a
local paediatric day unit.
While there is no consensus on the optimal age of diagnosis
of DMD, an early diagnosis is likely to result in better oppor-
tunities for optimised care and access to innovative clinical
trials. Some recent data suggest that early steroid treatment
(before the age of 4) might result in better long-term outcomes
including prolonged ambulation and delayed development of
cardiac and respiratory involvement.14 Only early diagnosis will
allow us to investigate these preliminary results further and
balance benefits and side effects of corticosteroids in younger
children. Moreover, early diagnosis will prepare this population
for therapeutic approaches currently in clinical trials or in devel-
opment, including gene therapy, exon skipping and cell therap-
ies, which are likely to be most successful in early stages of the
condition when the muscles are less damaged and therefore in
young children. Finally, as in the UK the average age between
siblings is 35 months, an early diagnosis is critical to allow
parents to make informed choices regarding family planning.15
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